NCT07491016Recruiting
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 18 Mar 2026
- Start date
- Mar 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Zhejiang Provincial People's Hospital
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07491016
What you commit to
- Study type: Observational
- Planned participants: 30
- From Mar 2026 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
- 2\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
- 3\. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
- 4\. Active tuberculosis or active infectious diseases requiring systemic treatment
- 6\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due
- 7\. Other conditions contraindicating participation per investigator judgment
Other
- 5\. Pregnancy, lactation, or refusal to use contraception during the study
- to:Non-adherence or Severe adverse reactions
Who the study is looking for
- 1\. Age 18-85 years
- 2\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
- 3\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
- 4\. Voluntarily provided written informed consent
Age in the registry: 18 years to 85 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.